Every 10-Q that Instil Bio, Inc. (TIL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TIL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TIL filings page.
Instil Bio, Inc. reported sharply lower operating expenses and losses for the three and six months ended June 30, 2026 as it winds down prior programs and repositions for new in-licensing opportunities. Total operating expenses fell to $5.6 million for the quarter and $12.6 million year-to-date, driven by the discontinuation of AXN-2510 and earlier CoStAR-TIL programs, lower headcount, and reduced development and professional costs.
The company posted a net loss of $4.3 million for the quarter and $8.5 million for the first half, versus much higher losses a year earlier, while generating $4.5 million in rental income from its Tarzana, California facility. Cash, cash equivalents, restricted cash and marketable securities totaled $69.9 million against an $85.6 million fixed-rate term loan secured by the Tarzana facility, due January 2027 with a one-year extension option management expects to exercise. The facility was reclassified from held for sale back to held and used, resulting in a modest $0.2 million net remeasurement loss. Management believes current resources, together with the planned loan extension, will fund operations beyond 2027, but future development will depend on securing new product candidates and potentially additional financing.
Instil Bio, Inc. reported a much smaller net loss of $4.2 million for the quarter ended March 31, 2026, compared with $28.2 million a year earlier, as total operating expenses fell to $7.0 million from $30.6 million following major restructuring and the discontinuation of AXN-2510.
The company held $74.7 million in cash, cash equivalents, restricted cash and marketable securities and generated $2.2 million in rental income from its Tarzana facility, carried at $112.1 million as assets held for sale. Instil has an $85.6 million term loan maturing in January 2027, exceeding its liquid assets, which management identified as an indicator of substantial doubt about its ability to continue as a going concern. Management plans to exercise a contractual option to extend the loan to January 2028 and may refinance, sell the Tarzana facility, or raise additional equity or debt, and concluded these plans alleviate that substantial doubt.
Instil Bio, Inc. filed its Q3 2025 report, showing continued R&D investment and a narrower quarterly loss. The company reported a net loss of $13.6 million for the three months ended September 30, 2025. Cash, cash equivalents, restricted cash, marketable securities and long‑term investments totaled $83.4 million as of September 30, 2025.
Operating expenses were $15.0 million in the quarter, led by research and development of AXN‑2510/IMM2510 at $9.1 million, while general and administrative expenses were $5.9 million. Other rental income from the Tarzana facility contributed $2.2 million in the quarter. The Tarzana land and building were classified as assets held for sale at $112.1 million as of September 30, 2025.
Debt consisted of an outstanding principal of $85.6 million under a term loan bearing 6.35% interest, with interest‑only payments. During the nine months ended September 30, 2025, Instil raised $6.6 million net via its at‑the‑market program, issuing 185,837 shares. Shares outstanding were 6,781,976 as of November 11, 2025.
Instil Bio, Inc. reported a net loss of $21.4 million for the quarter and $49.6 million for the six months ended June 30, 2025, driven by increased R&D activity and restructuring and impairment charges of $16.6 million related to listing the Tarzana facility for sale. The company recognized a $10.0 million in-process R&D charge tied to a development milestone under its ImmuneOnco collaboration after IND clearance for AXN-2510/IMM2510 in the U.S.
The balance sheet shows $103.6 million of cash, cash equivalents, restricted cash, marketable securities and long-term investments and assets held for sale of $112.1 million (Tarzana). Debt includes a $85.6 million term loan (interest-only at 6.35%, two-year term). Management states current resources are expected to fund operations beyond 2026, and the company completed an ATM sale for $6.6 million in Q2.